Glycoprotein IIb/IIIa antagonists: a systematic review of randomized clinical trials in patients undergoing percutaneous coronary intervention

Canadian Coordinating Office for Health Technology Assessment
Record ID 32005000130
English, French
Authors' objectives:

To assess the efficacy and safety of intravenously administered glycoprotein IIb/IIIa in patients undergoing a percutaneous coronary intervention for the treatment of acute myocardial infarction or acute coronary syndrome. Technology name: glycoprotein IIb/IIIa inhibitor drugs (abciximab, eptifibatide, tirofiban).

Authors' recommendations: These inhibitor drugs significantly reduce myocardial infarction and re-narrowing of coronary arteries at seven days, 30 days, and six months after a percutaneous coronary intervention. Most of the evidence is derived from trials on abciximab, the most widely studied agent. Eptifibatide and tirofiban are not found to be superior to abciximab. The death rate with abciximab treatment is reduced. This reduction is only significant at 30 days after an intervention. The other two agents are not associated with any significant reduction in risk of death. The beneficial effect of these inhibitor drugs must be weighed against the potential for a significant increase in minor bleeding.
Authors' methods: Systematic review
Details
Project Status: Completed
URL for project: https://www.ccohta/publications/pdf/163_glycoproteins_tr_e1.pdf
Year Published: 2005
English language abstract: An English language summary is available
Publication Type: Not Assigned
Country: Canada
MeSH Terms
  • Platelet Aggregation Inhibitors
  • Platelet Glycoprotein GPIIb-IIIa Complex
Contact
Organisation Name: Canadian Coordinating Office for Health Technology Assessment
Contact Address: 600-865 Carling Avenue, Ottawa, ON K1S 5S8 Canada. Tel: +1 613 226 2553, Fax: +1 613 226 5392;
Contact Name: requests@cadth.ca
Contact Email: requests@cadth.ca
Copyright: Canadian Coordinating Office for Health Technology Assessment (CCOHTA)
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.